A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
- Conditions
- Human Immunodeficiency Virus (HIV)
- Registration Number
- NCT00992654
- Lead Sponsor
- ViiV Healthcare
- Brief Summary
The new protocol will allow the patients enrolled on A4001050 to have continuous access of Maraviroc and the treatment will not be interrupted until the drug is commercially available in India.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Subjects who complete the A4001050 study and are continuing to derive benefit from Maraviroc.
- Subjects who are willing and able to comply with scheduled visits, treatment plan and other study procedures.
Exclusion Criteria
- Subjects who discontinued in A4001050 study.
- Unable to provide consent.
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method